1217 related articles for article (PubMed ID: 8371153)
1. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
Lynch JJ; Cook JJ; Sitko GR; Holahan MA; Ramjit DR; Mellott MJ; Stranieri MT; Stabilito II; Zhang G; Lynch RJ
J Pharmacol Exp Ther; 1995 Jan; 272(1):20-32. PubMed ID: 7815334
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Wang K; Zhou X; Huang Y; Khalil M; Wiktor D; van Giezen JJ; Penn MS
Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
6. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
Lucchessi BR; Rote WE; Driscoll EM; Mu DX
Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289
[TBL] [Abstract][Full Text] [Related]
8. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
9. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
[TBL] [Abstract][Full Text] [Related]
10. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.
Shebuski RJ; Ramjit DR; Sitko GR; Lumma PK; Garsky VM
Thromb Haemost; 1990 Dec; 64(4):576-81. PubMed ID: 2084943
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis.
Collen D; Lu HR; Stassen JM; Vreys I; Yasuda T; Bunting S; Gold HK
Thromb Haemost; 1994 Jan; 71(1):95-102. PubMed ID: 8165652
[TBL] [Abstract][Full Text] [Related]
12. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
15. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
Lynch JJ; Sitko GR; Lehman ED; Vlasuk GP
Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
[TBL] [Abstract][Full Text] [Related]
18. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Kawasaki T; Sato K; Suzuki K; Sakai Y; Taniuchi Y; Kaku S; Yano S; Inagaki O; Tomioka K; Masuho Y; Yanagisawa I; Takenaka T
Thromb Haemost; 1998 Mar; 79(3):663-7. PubMed ID: 9531059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
